Brian D Cleaver

Brian D Cleaver,

Associate Program Director

Department: MD-POWELL GENE THERAPY CENTER
Business Phone: (352) 273-7610

Publications

2019
Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy.
Annals of translational medicine. 7(13) [DOI] 10.21037/atm.2019.05.56. [PMID] 31392202.
2016
A scalable method for the production of high-titer and high-quality adeno-associated type 9 vectors using the HSV platform.
Molecular therapy. Methods & clinical development. 3 [DOI] 10.1038/mtm.2016.31. [PMID] 27222839.
2015
Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning.
Human gene therapy. Clinical development. 26(3):185-93 [DOI] 10.1089/humc.2015.068. [PMID] 26390092.
2014
A simplified purification protocol for recombinant adeno-associated virus vectors.
Molecular therapy. Methods & clinical development. 1 [DOI] 10.1038/mtm.2014.34. [PMID] 26015974.
2014
Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV-GAA) gene vector in patients with Pompe disease.
Human gene therapy. Clinical development. 25(3):134-63 [DOI] 10.1089/humc.2014.2514. [PMID] 25238277.
2013
Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes.
Human gene therapy. 24(6):630-40 [DOI] 10.1089/hum.2012.250. [PMID] 23570273.
2013
Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa.
Human gene therapy. Clinical development. 24(1):23-8 [DOI] 10.1089/humc.2013.037. [PMID] 23692380.
2013
Preclinical Safety Studies for Aav2-Mertk Gene Therapy Vector for Retinitis Pigmentosa
Molecular Therapy. 21
2011
Pompe disease gene therapy.
Human molecular genetics. 20(R1):R61-8 [DOI] 10.1093/hmg/ddr174. [PMID] 21518733.
2009
Preclinical Toxicology and Biodistribution Studies of Recombinant Adeno-Associated Virus 1 (Ravv1) Human Acid Alpha-Flucosidase (Gaa) in Nzw Rabbits By Intrathoracic Direct Injection in the Diaphragm
Molecular Therapy. 17
2001
Effects of estradiol-17beta administration on steady-state messenger ribonucleic acid (MRNA) encoding equine alpha and LH/CGbeta subunits in pituitaries of ovariectomized pony mares.
Theriogenology. 55(5):1083-93 [PMID] 11322236.
View on: PubMed
2001
Effects of ovarian input on GnRH and LH secretion immediately postovulation in pony mares.
Theriogenology. 55(5):1095-106 [PMID] 11322237.
View on: PubMed
1997
Biochemical changes in the equine capsule following prostaglandin-induced pregnancy failure.
Molecular reproduction and development. 46(3):286-95 [PMID] 9041131.
View on: PubMed
1997
Comparative study between pony mares and ewes evaluating gonadotrophic response to administration of gonadotrophin-releasing hormone.
Journal of reproduction and fertility. 110(2):219-29 [PMID] 9306974.
View on: PubMed
1997
The effect of pulsatile gonadotropin-releasing hormone and estradiol administration on luteinizing hormone and follicle-stimulating hormone concentrations in pituitary stalk-sectioned ovariectomized pony mares.
Domestic animal endocrinology. 14(5):275-85 [PMID] 9347248.
View on: PubMed
1996
Molecular cloning and characterization of an estrogen-dependent porcine oviductal secretory glycoprotein.
Biology of reproduction. 55(6):1305-14 [PMID] 8949888.
View on: PubMed
1991
Effect of constant light exposure on circulating gonadotrophin levels and hypothalamic gonadotrophin-releasing hormone (GnRH) content in the ovariectomized pony mare.
Journal of reproduction and fertility. Supplement. 44:259-66 [PMID] 1795268.
View on: PubMed

Grants

Sep 2020 ACTIVE
Clinical Development of CAR T Cell Therapy Targeting CD70 in Primary Glioblastoma
Role: Co-Investigator
Funding: US ARMY MED RES ACQUISITION
Aug 2020 ACTIVE
Storage of Samples
Role: Principal Investigator
Funding: ATSENA THERAPEUTICS
Jun 2020 ACTIVE
Task Order 3 – Access and Transfer of rHSV-AAV9 and rHSV-CB-hFXN Production and Testing Methods and Associated Materials
Role: Principal Investigator
Funding: AAVANTIBIO
Nov 2018 – Dec 2019
Production and Testing of rAAV9-DES-hGAA
Role: Principal Investigator
Funding: LACERTA THERAPEUTICS
Sep 2018 – Jul 2019
Voyant TO #1 – GMP Site Audit
Role: Principal Investigator
Funding: VOYANT BIOTHERAPEUTICS LLC
Nov 2017 ACTIVE
AAV9-CK8-uDys5 Samples testing
Role: Principal Investigator
Funding: SOLID BIOSCIENCES INC
Nov 2016 ACTIVE
TO #1 – Access and Transfer of rAAV9-CMV-hAADC Production and Testing Methods
Role: Principal Investigator
Funding: PTC THERAPEUTICS
Oct 2016 – Sep 2018
Task Order 1 – Reagents preparations and pilot production of rAAV3 for Hemophilia
Role: Faculty
Funding: CHRISTIAN MEDICAL COLLEGE
Aug 2016 – Jan 2017
TO #11 – Production of rAAV9-CK8-hDys5 Test Article using the Herpes-simplex virus platform
Role: Faculty
Funding: SOLID GT LLC
Aug 2015 ACTIVE
Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Jul 2013 – Dec 2019
Re-MATCH: Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive Cell Therapy During Recovery from Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation
Role: Project Manager
Funding: US ARMY MED RES ACQUISITION

Contact Details

Phones:
Business:
(352) 273-7610
Emails: